Skip to main content
. 2022 Jan 24;28(7):1446–1459. doi: 10.1158/1078-0432.CCR-21-1846

Figure 5.

Figure 5. DNA-PK regulates glycolysis in in vivo and ex vivo models. A, DNA-PK interacts with ALDOA and PKM2 in C4–2 xenografts. B, Representative IHC images for H&E, pDNA-PK, and DNA-PK after DNA-PK inhibition (25 mg/kg, 4 continuous days) effect. C and D, DNA-PK inhibition does not impact PKM2 expression but reduces pyruvate kinase activity (C) and pyruvate levels (D) in vivo. E–G, DNA-PK inhibition (1 μmol/L, 6 days) reduces pDNA-PK levels (E), pyruvate kinase activity (F), and pyruvate levels (G) in PDE. H, DNA-PK inhibition reduces lactate synthesis ex vivo (*, P < 0.05; **, P < 0.01).

DNA-PK regulates glycolysis in in vivo and ex vivo models. A, DNA-PK interacts with ALDOA and PKM2 in C4–2 xenografts. B, Representative IHC images for H&E, pDNA-PK, and DNA-PK after DNA-PK inhibition (25 mg/kg, 4 continuous days) effect. C and D, DNA-PK inhibition does not impact PKM2 expression but reduces pyruvate kinase activity (C) and pyruvate levels (D) in vivo. E–G, DNA-PK inhibition (1 μmol/L, 6 days) reduces pDNA-PK levels (E), pyruvate kinase activity (F), and pyruvate levels (G) in PDE. H, DNA-PK inhibition reduces lactate synthesis ex vivo (*, P < 0.05; **, P < 0.01).